Replies to post #208887 on Biotech Values

[DewDiligence]

Almost all of ENTA’s CC Q&A was about EDP-305, the FXR agonist for NASH and PBC.

[DewDiligence]

ENTA reports FY2Q17 financial results:

https://finance.yahoo.com/news/enanta-pharmaceuticals-reports-financial-results-200100447.html

Cash at 3/31/17 was $240.9M, a decrease of $3.5M from the 12/31/16 amount (#msg-128545809).

CC at 4:30pm ET.